Molecular Formula | C12H12F2O2 |
Molar Mass | 226.22 |
Density | 1.257±0.06 g/cm3(Predicted) |
Boling Point | 262.7±40.0 °C(Predicted) |
Storage Condition | Sealed in dry,Room Temperature |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 4.42 ml | 22.102 ml | 44.205 ml |
5 mM | 0.884 ml | 4.42 ml | 8.841 ml |
10 mM | 0.442 ml | 2.21 ml | 4.42 ml |
5 mM | 0.088 ml | 0.442 ml | 0.884 ml |
use | (1R,2R)-2-(3, 4-difluorophenyl) cyclopropanecarboxylate ethyl ester is a key intermediate in the synthesis of ticagrelor (ticagrelor). Ticagrel, chemical name [1S-[1 α,2 α,3 β(1S,2R),5 β]]-3-[7-[2-(3, 4-difluorophenyl)-cyclopropylamine]-5-(propylthio)-3H-1,2, 3-triazolo [4,5-d] pyrimidine-3-yl]-5-(2-hydroxyethoxy) cyclopentan-1, 2-diol is an oral antiplatelet drug developed by AstraZeneca (AstraZenecaAB). The drug can reversibly act on ADPP2Y12 receptors, has a significant inhibitory effect on platelet aggregation caused by ADP, and has a rapid oral effect. It is clinically used to reduce the incidence of thrombotic cardiovascular events in patients with acute coronary syndrome. |